利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

396 records (took 0.035 seconds)

    FCRN ANTIBODIES AND METHODS OF USE THEREOF
    1.
    发明申请
    FCRN ANTIBODIES AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：WO2019118791A1

    公开(公告)日：2019-06-20

    申请号：PCT/US2018/065568

    申请日：2018-12-13

    Applicant: MOMENTA PHARMACEUTICALS, INC.

    Inventor： HILLSON, Jan

    IPC: A61K39/395 ,  C07K16/28 ,  A61P37/00

    CPC classification number: C07K16/283 ,  A61K39/3955 ,  A61K2039/505 ,  A61P37/00 ,  C07K2317/565

    Abstract: The present invention features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

    CANCER GENE THERAPY TARGETING CD47
    4.
    发明申请
    CANCER GENE THERAPY TARGETING CD47 审中-公开
    癌基因治疗以CD47为目标

    公开(公告)号：WO2017184553A1

    公开(公告)日：2017-10-26

    申请号：PCT/US2017/028050

    申请日：2017-04-18

    Applicant: BAYLOR COLLEGE OF MEDICINE

    Inventor： GOTTSCHALK, Stephen, M., G. ,  CAO, Felicia

    IPC: A61K38/17 ,  A61K47/48 ,  C07K14/705 ,  C07K16/28

    CPC classification number: C07K16/2803 ,  A61K38/00 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/005 ,  A61K2039/505 ,  A61P35/00 ,  C07K14/705 ,  C07K14/70596 ,  C07K16/283 ,  C07K2317/622 ,  C07K2319/30 ,  Y02A50/465

    Abstract: Embodiments of the disclosure concern treatment of cancer utilizing methods and compositions that block CD47 such that tumor associated macrophages (TAMs) are not inhibited by CD47 and are able to phagocytose and kill tumor cells. In specific embodiments, the compositions and their use concern fusions of an entity that binds CD47 and an entity that binds cells having FC receptors, such as the FC receptor on TAMs. Certain embodiments concern gene therapy that produces a fusion of the ectodomain of SIRPa and the constant region of IgG4 at a localized tumor or tumor microenvironment, for example. In specific cases, gene transfer is utilized to deliver SIRPa fusion genes into a tumor and/or tumor microenvironment so that the molecules can be expressed locally to increase efficacy (given that the expression of the molecules will be highest at tumor sites) and decrease potential toxicities.

    Abstract translation: 本公开的实施方案涉及利用阻断CD47的方法和组合物治疗癌症，使得肿瘤相关巨噬细胞（TAM）不被CD47抑制并且能够吞噬和杀死肿瘤细胞。 在具体的实施方案中，组合物及其用途涉及结合CD47的实体和结合具有FC受体的细胞如TAM上的FC受体的实体的融合体。 例如，某些实施方案涉及在局部肿瘤或肿瘤微环境中产生SIRPa的胞外域和IgG4的恒定区的融合的基因疗法。 在特定情况下，利用基因转移将SIRPa融合基因输送到肿瘤和/或肿瘤微环境中，使得分子可以局部表达以增加功效（鉴于分子的表达在肿瘤位点处最高）并降低潜能 毒性

Patent Agency Ranking